AbbVie (ABBV) Free Cash Flow Growth (3y) (2015 - 2026)
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
FCF Growth (3y) (Qtr) |
| 1 |
Novartis Ag |
107,124,802.25 Bn |
107,124,802.25 Bn |
- |
27.23% |
| 2 |
Eli Lilly |
969.00 Bn |
963.72 Bn |
16.22 Bn |
41.47% |
| 3 |
Johnson & Johnson |
539.46 Bn |
517.41 Bn |
15.96 Bn |
-15.10% |
| 4 |
AbbVie |
376.92 Bn |
367.57 Bn |
10.78 Bn |
-3.92% |
| 5 |
Merck |
285.00 Bn |
279.35 Bn |
12.09 Bn |
106.58% |
| 6 |
Amgen |
177.58 Bn |
165.55 Bn |
5.87 Bn |
27.06% |
| 7 |
Gilead Sciences |
163.22 Bn |
155.50 Bn |
5.52 Bn |
14.07% |
| 8 |
Pfizer |
145.86 Bn |
133.09 Bn |
-1.21 Bn |
210.20% |
| 9 |
Bristol Myers Squibb |
111.90 Bn |
101.44 Bn |
8.07 Bn |
-34.49% |
| 10 |
Gsk |
88.34 Bn |
83.66 Bn |
- |
- |
| Date | Value |
| Mar 31, 2026 |
-3.92% |
| Dec 31, 2025 |
-12.17% |
| Sep 30, 2025 |
-3.64% |
| Jun 30, 2025 |
0.15% |
| Mar 31, 2025 |
-33.43% |
| Dec 31, 2024 |
11.40% |
| Sep 30, 2024 |
-12.34% |
| Jun 30, 2024 |
-24.38% |
| Mar 31, 2024 |
-6.38% |
| Dec 31, 2023 |
-0.20% |
| Sep 30, 2023 |
9.43% |
| Jun 30, 2023 |
28.24% |
| Mar 31, 2023 |
2.88% |
| Dec 31, 2022 |
32.35% |
| Sep 30, 2022 |
19.05% |
| Jun 30, 2022 |
27.44% |
| Mar 31, 2022 |
17.71% |
| Dec 31, 2021 |
14.35% |
| Sep 30, 2021 |
22.08% |
| Jun 30, 2021 |
19.49% |
| Mar 31, 2021 |
22.90% |
| Dec 31, 2020 |
23.96% |
| Sep 30, 2020 |
273.53% |
| Jun 30, 2020 |
202.82% |
| Mar 31, 2020 |
22.51% |
| Dec 31, 2019 |
29.68% |
| Sep 30, 2019 |
48.61% |
| Jun 30, 2019 |
9.54% |
| Mar 31, 2019 |
13.18% |
| Dec 31, 2018 |
21.60% |
| Sep 30, 2018 |
27.89% |
| Jun 30, 2018 |
17.03% |
| Mar 31, 2018 |
20.60% |
| Dec 31, 2017 |
74.20% |
| Sep 30, 2017 |
-27.44% |
| Jun 30, 2017 |
-27.48% |
| Mar 31, 2017 |
60.33% |
| Dec 31, 2016 |
9.26% |
| Sep 30, 2016 |
-6.96% |
| Jun 30, 2016 |
-2.33% |
| Mar 31, 2016 |
22.23% |
| Dec 31, 2015 |
29.04% |
| Sep 30, 2015 |
-3.65% |
| Jun 30, 2015 |
5.39% |
| Mar 31, 2015 |
0.19% |